Table 5.

CR and 1-y survival by mutational status and treatment arm

Mutationn (%; 95% CI) of patientsFisher’s exact P (2 sided)
Arm A: decitabine (n = 56)Arm B: decitabine + bortezomib (n = 62)
ASXL1n = 14n = 13
 CR*2 (14; 2-43)2 (15; 2-45)1.0
 1-y survival6 (43; 23-79)7 (54; 33-89).71
No ASXL1n = 42n = 49
 CR*8 (19; 9-34)13 (27; 15-41).46
 1-y survival16 (42; 29-60)23 (47; 35-63).52
DNMT3An = 9n = 14
 CR*1 (11; 0-48)3 (21; 5-51)1.0
 1-y survival3 (33; 7-70)7 (50; 23-77).67
No DNMT3An = 47n = 48
 CR*9 (19; 9-33)12 (25; 14-40).62
 1-y survival19 (40; 26-56)23 (48; 33-63).54
IDH2n = 8n = 9
 CR*2 (25; 3-65)2 (22; 3-60)1.0
 1-y survival5 (63; 24-91)7 (78; 40-97).62
No IDH2n = 48n = 53
 CR*8 (17; 7-30)13 (25; 14-40).46
 1-y survival17 (35; 22-51)23 (43; 30-58).42
NPM1n = 6n = 11
 CR*2 (33; 4-78)3 (27; 6-61)1.0
 1-y survival3 (50; 12-88)7 (64; 31-89).64
No NPM1n = 50n = 51
 CR*8 (16; 7-29)12 (24; 13-37).46
 1-y survival19 (38; 25-53)23 (45; 31-60).55
RUNX1n = 9n = 10
 CR*2 (22; 3-60)1 (10; 0-45).58
 1-y survival5 (56; 21-86)5 (50; 19-81)1.0
No RUNX1n = 47n = 52
 CR*8 (17; 8-31)14 (27; 67-41).33
 1-y survival17 (36; 23-51)25 (48; 34-62).31
TET2n = 8n = 12
 CR*1 (13; 0-53)3 (25; 5-57).62
 1-y survival3 (38; 9-76)6 (50; 21-79).67
No TET2n = 48n = 50
 CR*9 (19; 9-33)12 (24; 13-38).63
 1-y survival19 (40; 26-55)24 (48; 34-63).42
TP53n = 14n = 12
 CR*3 (21; 5-51)2 (17; 2-48)1.0
 1-y survival3 (27; 11-66)2 (17; 5-59)1.0
No TP53n = 42n = 50
 CR*7 (17; 7-31)13 (26; 15-40).32
 1-y survival19 (47; 34-65)28 (56; 44-72).40
  • * Binomial estimate for subgroups with ≤10 patients in a comparison.

  • Kaplan-Meier estimate.